Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model

Journal of Gene Medicine

Volumn 10, Issue 2, 2008, Pages 177-186

  El Gogo, Susanne ^a   Staib, Caroline ^a   Lasarte, Juan José ^b   Sutter, Gerd ^c   Adler, Heiko ^d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF NAVARRA   (Spain)

^c PAUL EHRLICH INSTITUT   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Hepatitis C virus; Immunization; Recombinant adenovirus; Recombinant MHV 68; Recombinant MVA; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; CD8 ANTIGEN; HEPATITIS C ANTIGEN; HEPATITIS C CORE ANTIGEN; HEPATITIS C VACCINE; HERPESVIRUS VECTOR; NONSTRUCTURAL PROTEIN 3; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; HEPATITIS C; HERPES VIRUS; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LATENT VIRUS INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS LOAD; VIRUS RECOMBINANT;

ANIMALS; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIGENS; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; NIH 3T3 CELLS; T-LYMPHOCYTES; VACCINATION; VIRAL CORE PROTEINS; VIRAL HEPATITIS VACCINES; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

ADENOVIRIDAE; ANIMALIA; HEPATITIS C VIRUS; MURINAE; MURINE HEPATITIS VIRUS; MUS; VACCINIA VIRUS ANKARA;

EID: 39449097886     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1144     Document Type: Article

References (52)

1. El-Gogo S, Staib C, Meyr M, Erfle V, Sutter G, Adler H. Recombinant murine gammaherpesvirus 68 (MHV-68) as challenge virus to test efficacy of vaccination against chronic virus infections in the mouse model. Vaccine 2007; 25: 3934-3945.
2. Geissler M, Tokushige K, Wakita T, Zurawski VR Jr, Wands JR. Differential cellular and humoral immune responses to HCV core and HBV envelope proteins after genetic immunizations using chimeric constructs. Vaccine 1998; 16: 857-867.
3. Inchauspe G, Vitvitski L, Major ME, et al. Plasmid DNA expressing a secreted or a nonsecreted form of hepatitis C virus nucleocapsid: comparative studies of antibody and T-helper responses following genetic immunization. DNA Cell Biol 1997; 16: 185-195.
4. McLauchlan J. Properties of the hepatitis C virus core protein: a structural protein that modulates cellular processes. J Viral Hepat 2000; 7: 2-14.
5. Bergqvist A, Rice CM. Transcriptional activation of the interleukin-2 promoter by hepatitis C virus core protein. J Virol 2001; 75: 772-781.
6. Battegay M, Pikes J, Di Bisceglie AM, et al. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol 1995; 69: 2462-2470.
7. Cerny A, McHutchison JG, Pasquinelli C, et al. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest 1995; 95: 521-530.
8. Diepolder HM, Gerlach JT, Zachoval R, et al. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 1997; 71: 6011-6019.
9. Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000; 6: 578-582.
10. Kato N, Ootsuyama Y, Sekiya H, et al. Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection. J Virol 1994; 68: 4776-4784.
11. Messerle M, Crnkovic I, Hammerschmidt W, Ziegler H, Koszinowski UH. Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. Proc Natl Acad Sci USA 1997; 94: 14759-14763.
12. Adler H, Messerle M, Wagner M, Koszinowski UH. Cloning and mutagenesis of the murine gammaherpesvirus 68 genome as an infectious bacterial artificial chromosome. J Virol 2000; 74: 6964-6974.
13. Staib C, Drexler I, Ohlmann M, Wintersperger S, Erfle V, Sutter G. Transient host range selection for genetic engineering of modified vaccinia virus Ankara. Biotechniques 2000; 28: 1137-1148.
14. Staib C, Lowel M, Erfle V, Sutter G. Improved host range selection for recombinant modified vaccinia virus Ankara. Biotechniques 2003; 34: 694-698.
15. Staib C, Sutter G. Live viral vectors: vaccinia virus. Methods Mol Med 2003; 87: 51-68.
16. Bruna-Romero O, Lasarte JJ, Wilkinson G, et al. Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus. Hepatology 1997; 25: 470-477.
17. Arribillaga L, de Cerio AL, Sarobe P, et al. Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus. Vaccine 2002; 21: 202-210.
18. Adler H, Messerle M, Koszinowski UH. Virus reconstituted from infectious bacterial artificial chromosome (BAC)-cloned murine gammaherpesvirus 68 acquires wild-type properties in vivo only after excision of BAC vector sequences. J Virol 2001; 75: 5692-5696.
19. Frelin L, Alheim M, Chen A, et al. Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4 A inhibit NS3/4A-expressing tumors in vivo. Gene Ther 2003; 10: 686-699.
20. Staib C, Kisling S, Erfle V, Sutter G. Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. J Gen Virol 2005; 86: 1997-2006.
21. Virgin HWIV, Latreille P, Wamsley P, et al. Complete sequence and genomic analysis of murine gammaherpesvirus 68. J Virol 1997; 71: 5894-5904.
22. Nash AA, Dutia BM, Stewart JP, Davison AJ. Natural history of murine γ-herpesvirus infection. Phil Trans R Soc Lond B 2001; 356:569-579.
23. Stevenson PG, Boname JM, de Lima B, Efstathiou S. A battle for survival: immune control and immune evasion in murine gamma-herpesvirus-68 infection. Microbes Infect 2002; 4: 1177-1182.
24. Usherwood EJ, Ross AJ, Allen DJ, Nash AA. Murine gammaherpesvirus-induced splenomegaly: a critical role for CD4 T cells. J Gen Virol 1996; 77: 627-630.
25. Sunil-Chandra NP, Efstathiou S, Nash AA. Murine gammaherpesvirus 68 establishes a latent infection in mouse B lymphocytes in vivo. J Gen Virol 1992; 73: 3275-3279.
26. Weck KE, Kim SS, Virgin HWIV, Speck SH. Macrophages are the major reservoir of latent murine gammaherpesvirus 68 in peritoneal cells. J Virol 1999; 73: 3273-3283.
27. Flano E, Husain SM, Sample JT, Woodland DL, Blackman MA. Latent murine γ-herpesvirus infection is established in activated B cells, dendritic cells, and macrophages. J Immunol 2000; 165: 1074-1081.
28. Stewart JP, Usherwood EJ, Ross A, Dyson H, Nash T. Lung epithelial cells are a major site of murine gammaherpesvirus persistence. J Exp Med 1998: 187: 1941-51.
29. Willer DO, Speck SH. Long-term latent murine Gammaherpesvirus 68 infection is preferentially found within the surface immunoglobulin D-negative subset of splenic B cells in vivo. J Virol 2003; 77: 8310-8321.
30. Flano E, Kim IJ, Woodland DL, Blackman MA. Gammaherpesvirus latency is preferentially maintained in splenic germinal center and memory B cells. J Exp Med 2002; 196: 1363-1372.
31. Marques S, Efstathiou S, Smith KG, Haury M, Simas JP. Selective gene expression of latent murine gammaherpesvirus 68 in B lymphocytes. J Virol 2003; 77: 7308-7318.
32. Virgin HWIV, Speck SH. Unraveling immunity to γ-herpesviruses: a new model for understanding the role of immunity in chronic virus infection. Curr Opin Immunol 1999; 11:371-379.
33. Diepolder HM, Zachoval R, Hoffmann RM, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346: 1006-1007.
34. Thimme R, Oldach D, Chang IM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194: 1395-1406.
35. Ulsenheimer A, Lucas M, Seth NP, et al. Transient immunological control during acute hepatitis C virus infection: ex vivo analysis of helper T-cell responses. J Viral Hepat 2006; 13: 708-714.
36. Gerlach JT, Ulsenheimer A, Gruner NH, et al. Minimal T-cell-stimulatory sequences and spectrum of HLA restriction of immunodominant CD4+ T-cell epitopes within hepatitis C virus NS3 and NS4 proteins. J Virol 2005; 79: 12425-12433.
37. Gruener NH, Jung MC, Ulsenheimer A, et al. Analysis of a successful HCV-specific CD8+ T cell response in patients with recurrent HCV-infection after orthotopic liver transplantation. Liver Transpl 2004; 10: 1487-1496.
38. Schirren CA, Zachoval R, Gerlach JT, et al. Antiviral treatment of recurrent hepatitis C virus (HCV) infection after liver transplantation: association of a strong, multispecific, and long-lasting CD4+ T cell response with HCV-elimination. J Hepatol 2003; 39: 397-404.
39. Nascimbeni M, Mizukoshi E, Bosmann M, et al. Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol 2003; 77: 4781-4793.
40. Major ME, Mihalik K, Puig M, et al. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol 2002; 76: 6586-6595.
41. Grakoui A, Shoukry NH, Woollard DJ, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003; 302: 659-662.
42. Shoukry NH, Grakoui A, Houghton M, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003; 197: 1645-1655.
43. Kittlesen DJ, Chianese-Bullock KA, Yao ZQ, Braciale TJ, Hahn YS. Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. J Clin Invest 2000; 106: 1239-1249.
44. Eisen-Vandervelde AL, Waggoner SN, Yao ZQ, Cale EM, Hahn CS, Hahn YS. Hepatitis C virus core selectively suppresses interleukin-12 synthesis in human macrophages by interfering with AP-1 activation. J Biol Chem 2004; 279: 43479-43486.
45. Yao ZQ, Eisen-Vandervelde A, Waggoner SN, Cale EM, Hahn YS. Direct binding of hepatitis C virus core to gC1qR on CD4+ and CD8+ T cells leads to impaired activation of Lck and Akt. J Virol 2004; 78: 6409-6419.
46. Folgori A, Capone S, Ruggeri L, et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 2006; 12: 190-197.
47. Gonzalez-Aseguinolaza G, Nakaya Y, Molano A, et al. Induction of protective immunity against malaria by priming-boosting immunization with recombinant cold-adapted influenza and modified vaccinia Ankara viruses expressing a CD8+-T-cell epitope derived from the circumsporozoite protein of Plasmodium yoelii. J Virol 2003; 77: 11859-11866.
48. Fischer MA, Tscharke DC, Donohue KB, Truckenmiller ME, Norbury CC. Reduction of vector gene expression increases foreign antigen-specific CD8+ T-cell priming. J Gen Virol 2007; 88: 2378-2386.
49. Shirai M, Arichi T, Nishioka M, et al. CTL responses of HLA-A2. 1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J Immunol 1995; 154: 2733-2742.
50. Large MK, Kittlesen DJ, Hahn YS. Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J Immunol 1999; 162: 931-938.
51. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 2005; 436: 961-966.
52. Rollier C, Paranhos-Baccala G, Verschoor E, et al. Vaccine-induced early control of Hepatitis C virus infection in chimpanzees fails to impact on hepatic PD1 and chronicity. Hepatology 2007; 45: 602-613.